BPTS - Earnings announcements

Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for the drug Sarconeos (BIO101) developed by Biophytis in the context of the early access program application.The application request for early access program, currently underway with the Haute Autorité de Santé (the French National Authority for Health, HAS), aims to allow treatment with Sarconeos (BIO101) for hospitalized patients with severe forms of COVID-19 as of the second half of 2023.PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 2, 2023 / Biophytis SA (NASDAQ:BPTS)(PARIS:ALBPS) (the "Company" or "Biop

Biophytis to present the early access application in France at a pre-filing meeting in March with the HASBiophytis plans to file the application shortly after with the objective of obtaining early access authorization in France in the second quarter of 2023Biophytis is pursuing in parallel the preparation of the conditional marketing authorization application due to the health emergency in Europe and the United StatesPARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / February 27, 2023 / Biophytis SA ((NasdaqCM: BPTS, PARIS:ALBPS) (the "Company" or "Biophytis"), a biotechnology company focused on the development of drugs to slow the degenerative processes associated with aging, including severe res

Cash and cash equivalents: €19.7m as of June 30, 2022Net loss down 8% at €12.4m for first half of 2022Publication of restated financial results as of December 31st, 2021PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / January 31, 2023 / Biophytis SA ((NasdaqCM:BPTS, PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today publishes its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021.Financial results for the first half of 2022C